Drug Trial Radar · NCT07665684
Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer
Last checked: Nov 19, 2026Latest source record: Jun 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
67
Planned (sponsor's estimate)
Start
Jul 2026
Primary completion
May 2029
Study completion May 2030
Sponsor
- Lead sponsor
- University Health Network, TorontoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to find the highest dose of a drug, samuraciclib, that can be given with standard of care chemotherapy (gemcitabine and nab-paclitaxel) without causing very severe side effects. This is done by starting at a dose lower than the one that is used when samuraciclib is taken by itself without chemotherapy. The main question it aims to answer is: • For patients with newly diagnosed metastatic pancreatic cancer, what is the safety and tolerability of samuraciclib with gemcitabine/nab-paclitaxel? Participants will: * Undergo a tumor biopsy. * Be treated with samuraciclib in combination with their standard of care chemotherapy (gemcitabine/nab-paclitaxel). * Donate research blood samples.
Conditions
- Pancreas Ductal Adenocarcinoma
- Pancreas Cancer, Metastatic
- Pancreatic Adenocarcinoma Metastatic
- Adenosquamous Carcinoma of the Pancreas
- Mucinous Adenocarcinoma
Interventions
Samuraciclib + Gemcitabine & Nab-PaclitaxelDrug
Starting dose level: Samuraciclib 240 mg taken orally, once daily. Gemcitabine 1000 mg/m2 and nab-paclitaxel 125 mg/m2 on days 1, 8 and 15.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequencies of adverse events (AEs), as graded by CTCAE v6.0 and reported by dose levelTime frame: From date of enrollment to date off treatment, assessed up to 24 months
- Percentages of adverse events (AEs), as graded by CTCAE v6.0 and reported by dose levelTime frame: From date of enrollment to date off treatment, assessed up to 24 months
- Frequencies of dose-limiting toxicities reported by dose levelTime frame: From date of enrollment to date off treatment, assessed up to 24 months
- Percentages of dose-limiting toxicities reported by dose levelTime frame: From date of enrollment to date off treatment, assessed up to 24 months
- Maximum tolerated dose, defined as the highest dose level where a dose-limiting toxicity occurs within at most one out of six patients treatedTime frame: From date of enrollment to date off treatment, assessed up to 24 months
- Recommended phase II dose (RP2D)Time frame: From date of enrollment to date off treatment, assessed up to 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.